@article{3015e2ba566d405eb706480087c4c210,
title = "Sleep Apnea and Atrial Fibrillation",
abstract = "Obstructive sleep apnea (OSA) creates a complex and dynamic substrate for atrial fibrillation (AF), which is characterized by structural remodeling as a result of long-term OSA as well as transient and acute apnea-associated transient atrial electrophysiological changes. OSA is present in 21% to 74% of patients with AF, and nonrandomized studies suggest that treatment of OSA by continuous positive airway pressure may help to maintain sinus rhythm after electrical cardioversion and improve catheter ablation success rates. Management of OSA in patients with AF requires a close interdisciplinary collaboration between the electrophysiologist/cardiologist and sleep specialists.",
keywords = "Atrial Fibrillation, Catheter Ablation, Continuous Positive Airway Pressure, Humans, Sleep Apnea Syndromes",
author = "Dominik Linz and Stanley Nattel and Kalman, {Jonathan M} and Prashanthan Sanders",
note = "Funding Information: Dr D. Linz is supported by a Beacon Research Fellowship by the University of Adelaide. Drs J.M. Kalman and P. Sanders are supported by Practitioner Fellowships from the National Health and Medical Research Council of Australia. Dr P. Sanders is supported by the National Heart Foundation of Australia. Dr D. Linz reports having served on the advisory board of LivaNova, Respicardia, and Medtronic. Dr D. Linz reports having received lecture and/or consulting fees from LivaNova, Biosense-Webster, Medtronic, Pfizer, Bayer, and ResMed. Dr D. Linz reports having received research funding from Sanofi, ResMed, and Medtronic. Dr P. Sanders reports having served on the advisory board of Biosense-Webster, Medtronic, St Jude Medical, Boston Scientific, and CathRx. Dr P. Sanders reports having received lecture and/or consulting fees from Biosense-Webster, Medtronic, St Jude Medical, and Boston Scientific. Dr P. Sanders reports having received research funding from Medtronic, St Jude Medical, Boston Scientific, Biotronik, and Sorin. The other authors have nothing to disclose. Funding Information: Dr D. Linz is supported by a Beacon Research Fellowship by the University of Adelaide . Drs J.M. Kalman and P. Sanders are supported by Practitioner Fellowships from the National Health and Medical Research Council of Australia . Dr P. Sanders is supported by the National Heart Foundation of Australia . Dr D. Linz reports having served on the advisory board of LivaNova, Respicardia, and Medtronic. Dr D. Linz reports having received lecture and/or consulting fees from LivaNova, Biosense-Webster, Medtronic, Pfizer, Bayer, and ResMed. Dr D. Linz reports having received research funding from Sanofi , ResMed , and Medtronic . Dr P. Sanders reports having served on the advisory board of Biosense-Webster, Medtronic, St Jude Medical, Boston Scientific, and CathRx. Dr P. Sanders reports having received lecture and/or consulting fees from Biosense-Webster, Medtronic, St Jude Medical, and Boston Scientific. Dr P. Sanders reports having received research funding from Medtronic , St Jude Medical , Boston Scientific , Biotronik , and Sorin . The other authors have nothing to disclose. Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",
year = "2021",
month = mar,
doi = "10.1016/j.ccep.2020.10.003",
language = "English",
volume = "13",
pages = "87--94",
journal = "Cardiac Electrophysiology Clinics",
issn = "1877-9182",
publisher = "W.B. Saunders Co.",
number = "1",
}